This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 Aug 10;35(23):2595-2597.

doi: 10.1200/JCO.2017.73.2586. Epub 2017 May 18.

Expanding the Roster of ROS1 Inhibitors

Ibiayi Dagogo-Jack¹, Alice T Shaw¹

Affiliations

PMID: 28520528
DOI: 10.1200/JCO.2017.73.2586

Editorial

Expanding the Roster of ROS1 Inhibitors

Ibiayi Dagogo-Jack et al. J Clin Oncol. 2017.

. 2017 Aug 10;35(23):2595-2597.

doi: 10.1200/JCO.2017.73.2586. Epub 2017 May 18.

Authors

Ibiayi Dagogo-Jack¹, Alice T Shaw¹

Affiliation

¹ Ibiayi Dagogo-Jack and Alice T. Shaw, Massachusetts General Hospital, Boston, MA.

PMID: 28520528
DOI: 10.1200/JCO.2017.73.2586

No abstract available

PubMed Disclaimer

Comment on

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, Kim JH, Ali SM, Ahn MJ, Cho BC. Lim SM, et al. J Clin Oncol. 2017 Aug 10;35(23):2613-2618. doi: 10.1200/JCO.2016.71.3701. Epub 2017 May 18. J Clin Oncol. 2017. PMID: 28520527 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information